Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
03/2010
03/17/2010CN101669930A Medicament capable of radically treating cardiovascular and cerebrovascular diseases and hypertensions
03/17/2010CN101669929A Preparation method and application of ibuprofen liquid preparation
03/17/2010CN101669928A Slow-release composition containing antidepressant
03/17/2010CN101669927A Application of anthraquinone ZSU-H85 for preparing mycobacterium smegmatis resistant drugs
03/17/2010CN101669926A Liquid preparation for dosing nasal cavities and method for making the same
03/17/2010CN101669921A Gliclazide sustained-release capsule and preparation process thereof
03/17/2010CN101669920A Strong anti-oxidation DHA microcapsule and preparation method thereof
03/17/2010CN101669918A Aspirin double-releasing preparation and preparation method thereof
03/17/2010CN101669917A Scopolamine hydrobromide orally disintegrating microencapsule tablets based on NIMS system
03/17/2010CN101669916A Method for preparing nifedipine freeze-dried powder injection
03/17/2010CN101669915A Oridonin dry emulsion and preparation method thereof
03/17/2010CN101669913A Levocetirizine dihydrochloride granule and preparation and detection methods thereof
03/17/2010CN101669912A Slow-release composition containing tamsulosin and preparation thereof
03/17/2010CN101669911A Dicazuril soluble powder and preparation method thereof
03/17/2010CN101669910A Preparation of cefobutazine sodium proliposome
03/17/2010CN101669908A Preparing method of taxanes substance preparation with nanostructure
03/17/2010CN101669907A Oridonin emulsion
03/17/2010CN101669906A Praziquantel injection, preparation method and application thereof
03/17/2010CN101669904A Epoprostanol lipid nanoparticle and preparation method thereof
03/17/2010CN101669903A Preparation method of ibuprofen aminophenol injection
03/17/2010CN101669902A Polyene phosphatidyl choline injection and preparation method thereof
03/17/2010CN101669901A Liquid preparation for dosing eyes and method for making the same
03/17/2010CN101669898A Medicinal preparation for injective administration and preparation method thereof
03/17/2010CN101669637A Application of cornflower-3-O-galactoside in preparing foods or medicaments for improving cognitive functions of old people
03/17/2010CN100594214C Substituted oxazolobenzoisothiazole dioxide derivatives, production method and use thereof
03/17/2010CN100594213C N-[2-(5,5-dimethyl-1,3-dioxan-2-yl)-ethyl]amino acid and its synthesis and application
03/17/2010CN100594212C Polymorphic form of N-[(R)-2,3-dihydroxy-propoxy]-3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-benzamide
03/17/2010CN100594211C 4-methoxy-1,3-phenyl disubstituted amide derivative
03/17/2010CN100594036C Animal medicine capable of rehabilitating intestinal tract injury
03/17/2010CN100594032C Oral and external remedy for curing psoriasis
03/17/2010CN100594031C Tablet for keeping in mouth and its preparing method
03/17/2010CN100594030C Externally-used Chinese traditional medicine ointment for treating paronychia
03/17/2010CN100594029C Medicinal composition for injections in articular cavity
03/17/2010CN100594028C Composition containing chondroitin sulfate zinc and its application
03/17/2010CN100594027C Percutaneous medicine of strychnine, toxiferine, securinine and salt thereof
03/17/2010CN100594026C Pharmaceutical use of smallflower thinleaf crazyweed total alkaloid and azahexacyclonone derivative
03/17/2010CN100594025C Drop pills of hippophase rhamnoides and preparation method
03/17/2010CN100594024C Permeability nose absorption type medicine for treating and preventing senile dementia, improving learning memory faculty and regulating blood brain barrier
03/16/2010US7678946 2,4,6,-trisubstituted having anesthetic properties
03/16/2010US7678926 non-steroidal agonists and antagonists; 2-(2-ethylsulfanyl-1-hydroxy-1-methyl-ethyl)-6-trifluoromethyl-1H-benzofuran-5--carbonitrile; anticarcinogenic; prostate carcinoma, benign prostatic hyperplasia (BPH), hirsutism, alopecia, anorexia nervosa, breast cancer, AIDS, cachexia, as a male contraceptive
03/16/2010US7678923 Method for synthesizing 5-chloro-1-aryl-4-(4,5-dicyano-1h-imidazol-2-yl)-3-alkyl-1h-pyrazole derivatives
03/16/2010US7678920 [3-(6-Chloropyridin-3-yl)-2-methylpropyl](methyl)oxido- lambda 4-sulfanylidenecyanamide; aphidicides
03/16/2010US7678919 Method for producing pentacyclic taxans
03/16/2010US7678918 Induce the biosynthesis of cytokines such as interferon and tumor necrosis factor; antiviral and antitumor agents
03/16/2010US7678917 5-Chloro-thiophene-2-carboxylic acid {(1S,2S,4R)-4-[2-fluoro-4-(2-oxo-2H-pyridin-1-yl)-phenylcarbamoyl]-2-hydroxy-cyclopentyl}-amide; anticoagulant, antiinflammatory agent; thrombosis, peripheral arterial occlusive disease, stroke, arteriosclerosis, bypass grafting
03/16/2010US7678916 crystalline rosiglitazone maleate filtration
03/16/2010US7678915 Process for production of piperidine derivatives
03/16/2010US7678913 Ureas as factor Xa inhibitors
03/16/2010US7678909 Dipeptidyl peptidase inhibitors
03/16/2010US7678908 Process of preparing desaloratadine
03/16/2010US7678904 or to treat autoimmune and inflammatory disorders; improved water solubility characteristics
03/16/2010US7678896 Short interference RNA duplexes when introduced into mammalian cells in culture perform sequence-specific inhibition of target mRNA without inducing an interferon response; for gene silencing to treat human diseases; double stranded siRNA
03/16/2010US7678884 Biologically active peptide and agent containing the same
03/16/2010US7678836 Method for rendering a contact lens wettable
03/16/2010US7678834 Substituted 4-aminocyclohexanol compounds
03/16/2010US7678833 Method to increase the bioavailability of cysteine
03/16/2010US7678832 Bis(thio-hydrazide amide) formulation
03/16/2010US7678831 2-{2-[3-(4-chlorophenyl)acryloyl]-4-methylphenoxy}-4-phenylbutanoic acid; Peroxisome Proliferator Activated Receptors (PPAR); diabetes, dyslipidemia and/or atherosclerosis
03/16/2010US7678830 inhibiting excessive nitric oxide or prostaglandin formation; cancer, Alzheimer's disease, Parkinson's disease, multiple sclerosis, amyotropic lateral sclerosis, rheumatoid arthritis, inflammatory bowel disease
03/16/2010US7678829 Oculoselective drugs and prodrugs
03/16/2010US7678828 Methods for the formulation and manufacture of artesunic acid for injection
03/16/2010US7678827 Non-polymeric lipophilic pharmaceutical implant compositions for intraocular use
03/16/2010US7678825 Administering 2-[1-(3-Ethoxy-4-methoxyphenyl)2-methylsulfonylethyl]4,5-diaminoisoindoline-1,3-dione or salts to treat Crohn's disease, inflammatory bowel disease, psoriasis, rheumatoid arthritis, spondylitis, osteoarthritis, or ulcerative colitis; tumor necrosis factor and phosphodiesterase inhibitors
03/16/2010US7678824 Methods for treatment with bucindolol based on genetic targeting
03/16/2010US7678823 N-phenylindoles; oral dosage forms; side effect reduction
03/16/2010US7678822 inhibiting rejection of a transplanted organ, tissue or cell in a recipient mammal; immunosuppressive agent; autoimmune diseases
03/16/2010US7678821 comprising tolterodine and pilocarpine; drug releasing pilocarpine between about 15 minutes to about 30 minutes after tolterodine is released; depending on the peak of saliva flow time; urogenital disorders
03/16/2010US7678820 Hetero compound
03/16/2010US7678819 Acetylene derivatives and their use for binding and imaging amyloid plaques
03/16/2010US7678818 5-chloro-N-(4-cyclopentyl-benzyl)-2-isopropylamino-N-[2-(3-trifluoromethyl-phenyl)-ethyl]-benzamide; cholesteryl ester transfer protein (CETP) inhibitors; Atherosclerosis; cardiovascular disorders
03/16/2010US7678817 Enteric medicinal composition for oral use
03/16/2010US7678816 Method of stabilizing lansoprazole
03/16/2010US7678815 Thiazole-4-carboxyamide derivatives
03/16/2010US7678814 Aroyl-piperidine derivatives
03/16/2010US7678813 8a-Benzyl-2-(4-methoxyphenyl)-1,3,4,7,8,8a-hexahydro-2H-isoquinolin-6-one; psychotic major depression, schizoaffective disorder, Alzheimer's Disease and cocaine addiction
03/16/2010US7678812 Aminotetralin-derived urea modulators of vanilloid VR1 receptor
03/16/2010US7678811 An urea compounds containing a pyridine, quinoline, or isoquinoline functionality; p38 mediated diseases such as inflammation and VEGF mediated diseases such as angogenesis disorders
03/16/2010US7678810 activin receptor-like kinase 5 (ALK5) (which is a TGF- beta type I receptor) inhibitor ; glomerulonephritis, diabetic nephropathy, hepatic fibrosis, liver cirrhosis, pulmonary fibrosis, or alopeciarosis; hair growth stimulant
03/16/2010US7678809 Useful in the treatment of chronic and acute pain; 1-[4-dibenzocycloheptyl-4-piperidinyl]-1,3-dihydro-2H-1,3-benzamidazol-2-one;
03/16/2010US7678808 5 HT receptor mediated neurogenesis
03/16/2010US7678807 Isoquinoline and benzo[H] isoquinoline derivatives, preparation and therapeutic use thereof as antagonists of the histamine H3 receptor
03/16/2010US7678806 5-Bromo-1'-[(3-methyl-1H-inden-2-yl)carbonyl]spiro[indole-3,4'-piperidin]-2(1H); vasopressin receptor antagonist; antidepressant, anxiolytic agent; dysmenorrhea, hypertension, chronic heart failure, inappropriate secretion of vasopressin, liver cirrhosis, nephrotic syndrome, obsessive compulsive disorder
03/16/2010US7678805 inhibitors are unable to promote death of IL-3 dependent cells cultured in presence of IL-3; non-toxic, selective and potent
03/16/2010US7678804 Pyrimidine derivatives for treatment of hyperproliferative disorders
03/16/2010US7678803 Heat Shock Protein-90 inhibitors; Antiproliferative agents; cancer, inflammation, arthritis, angiogenesis, viral, fungal and malaria infections; 1-(isoquinoline, quinazoline or pyrimidino(3,2-d)pyridine-substituted)-4,5,6,7-tetrahydroindol-4-ones or 4,5,6,7-pyrazol-4-ones
03/16/2010US7678802 Voltage gated sodium and calcium channel inhibitors
03/16/2010US7678801 Compounds
03/16/2010US7678800 2-(1H-indolylsulfanyl)-aryl amine derivatives for use in the treatment of affective disorders, pain, ADHD and stress urinary incontinence
03/16/2010US7678799 Crystalline ziprasidone HCl and processes for preparation thereof
03/16/2010US7678798 5-({4-[(3S)-4-(5-bromo-2,3-dihydro-1H-inden-1-yl)-3-methylpiperazin-1-yl]-4-methylpiperidin-1-yl}carbonyl)-4,6-dimethylpyrimidine; inflammatory diseases, immune diseases and viral infections; HIV
03/16/2010US7678797 1-phenyl-3-piperazine-pyrazoles and pesticidal compositions of matter thereof
03/16/2010US7678796 MGluR5 modulators I
03/16/2010US7678795 (1S,8R)-5-Cyclopropyl-1,11,11-trimethyl-3,4-diaza-tricyclo[6.2.1.02,7]undeca-2(7),3,5-triene; type II diabetes; 11beta-hydroxysteroid dehydrogenase type 1 (11beta-HSD1)
03/16/2010US7678794 3-{[4-(4-acetyl-3-hydroxy-2-propylphenoxymethyl)-phenyl]-(S)-hydroxymethyl}-benzoic acid; anxiolytic, neuroleptic agent and antidepressant as glutamate receptor agonist; antiinflammatory agent as leukotriene receptor agonist;
03/16/2010US7678793 Azolo triazines and pyrimidines
03/16/2010US7678792 e.g. 3-(5-amino-2-methylphenyl)-7-chloro-1-methyl-1,6-naphthyridin-2(1H)-one; protein kinase inhibitor; antiinflammatory, anticarcinogenic, antiallergen, antidiabetic, antiischemic, hypotensive agent
03/16/2010US7678791 4-Deoxy-3,4-[2-spiro-[1-[2-(2-methyl-5-nitro-imidazol-1-yl)ethyl]-piperidin-4-yl]]-(1H)-imidazo-(2,5-dihydro)rifamycin; antibiotic resistance; synergistic effects of covalently linking antibacterial pharmacophores together; pharmacokinetics; aerobic, anaerobic gram-positive and gram-negative bacteria
03/16/2010US7678790 sulfonylurea derivatives, sulfonylthiourea derivatives, sulfonylguanidine derivatives, sulfonylcyanoguanidine derivatives, thioacylsulfonamide derivatives, and acylsulfonamide derivatives; effective for prevention and treatment of cardiovascular diseases, antithrombotic agents
03/16/2010US7678789 [1,2,4]-dithiazoli(di)ne derivatives, inducers of gluthathione-S-transferase and NADPH quinone oxido-reductase, for prophylaxis and treatment of adverse conditions associated with cytotoxicity in general and apoptosis in particular
03/16/2010US7678788 (1,4-Diaza-bicyclo[3.2.2]non-4-yl)-5-(4-nitrophenyl)-furan-2-yl-methanone; nicotinic acetylcholine receptor inhibitors; nervous system disorders, neurodegeneration, inflammation, pain, and withdrawal symptoms caused by the termination of abuse of chemical substances
1 ... 2350 2351 2352 2353 2354 2355 2356 2357 2358 2359 2360 2361 2362 2363 2364 2365 2366 2367 2368 2369 2370 ... 7860